Randomized Phase II Study of Amrubicin as Single Agent or in Combination With Cisplatin Versus Etoposide-cisplatin as First-line Treatment in Patients With Extensive Stage SCLC (ES).

Trial Profile

Randomized Phase II Study of Amrubicin as Single Agent or in Combination With Cisplatin Versus Etoposide-cisplatin as First-line Treatment in Patients With Extensive Stage SCLC (ES).

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Apr 2013

At a glance

  • Drugs Amrubicin (Primary) ; Cisplatin; Etoposide; Etoposide
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Jun 2011 Results published in the European Journal of Cancer.
    • 12 Apr 2011 Actual end date (December 2010) added as reported by ClinicalTrials.gov.
    • 12 Apr 2011 Actual end date (December 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top